Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report.
Aged
Cardiovascular Abnormalities
/ complications
Combined Modality Therapy
Humans
Hypertension
/ chemically induced
Male
Phenylurea Compounds
/ administration & dosage
Positron Emission Tomography Computed Tomography
Quinolines
/ administration & dosage
Radiofrequency Ablation
/ methods
Thyroid Cancer, Papillary
/ complications
cardiological comorbidity
lenvatinib
papillary thyroid cancer
tyrosine kinase inhibitor
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
pubmed:
9
8
2019
medline:
1
2
2020
entrez:
9
8
2019
Statut:
ppublish
Résumé
Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.
Identifiants
pubmed: 31393171
doi: 10.2217/fon-2019-0114
doi:
Substances chimiques
Phenylurea Compounds
0
Quinolines
0
lenvatinib
EE083865G2
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM